Pictet Asset Management (Switzerland)’s Sarepta Therapeutics SRPT Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$109M	Sell	953,003 -260,353	-21%	-$33.6M	0.13%	186
2023 Q1	$167M	Buy	1,213,356 +282,713	+30%	+$36.7M	0.21%	140
2022 Q4	$121M	Buy	930,643 +263,599	+40%	+$30.5M	0.17%	164
2022 Q3	$73.7M	Buy	667,044 +547,857	+460%	+$55.2M	0.11%	221
2022 Q2	$8.93M	Buy	119,187 +31,331	+36%	+$2.3M	0.01%	627
2022 Q1	$6.86M	Sell	87,856 -4,286	-5%	-$328K	0.01%	745
2021 Q4	$8.3M	Buy	92,142 +11,270	+14%	+$963K	0.01%	723
2021 Q3	$7.48M	Buy	+80,872	New	+$6.23M	0.01%	756

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s SRPT Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) reduced its Sarepta Therapeutics (SRPT) stake by 21% in Q2 2023, selling an estimated $33.6M and leaving 953,003 shares worth $109M. The position accounts for 0.13% of the portfolio, ranked #186.

Pictet Asset Management (Switzerland) first reported a position in SRPT in Q3 2021 and has held it in 8 quarters since. The position peaked at $167M in Q1 2023. 405 funds tracked by Wall St. Rank hold SRPT as of Q2 2023.

Pictet Asset Management (Switzerland) held 953,003 shares of Sarepta Therapeutics worth $109M as of Q2 2023.
Pictet Asset Management (Switzerland) sold 260,353 Sarepta Therapeutics shares in Q2 2023, an estimated $33.6M.
Sarepta Therapeutics made up 0.13% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #186 holding.
Pictet Asset Management (Switzerland) first reported a position in Sarepta Therapeutics in Q3 2021 and has held it in 8 quarters since.
Pictet Asset Management (Switzerland)'s Sarepta Therapeutics position peaked at $167M in Q1 2023.
405 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.